We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -1.00 | -0.07% | 1,459.50 | 8,609,818 | 16:35:21 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,459.00 | 1,459.50 | 1,462.00 | 1,439.00 | 1,456.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 12.27 | 60.54B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:51:42 | O | 298 | 1,459.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/10/2024 | 15:00 | UK RNS | GSK PLC Total Voting Rights |
| 24/9/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 24/9/2024 | 09:16 | ALNC |  TOP NEWS: GSK celebrates positive EU opinion of liquid Menveo vaccine |
| 24/9/2024 | 07:00 | UK RNS | GSK PLC Positive EU opinion for GSK liquid Menveo vaccine |
| 18/9/2024 | 14:00 | ALNC | GSK reaches further two settlements regarding Zantac |
| 18/9/2024 | 13:20 | UK RNS | GSK PLC Statement: Zantac (ranitidine) litigation |
| 17/9/2024 | 09:18 | ALNC | GSK says Blenrep combinations accepted for review in Japan |
| 17/9/2024 | 07:00 | UK RNS | GSK PLC Japan Filing Acceptance: Blenrep Multiple Myeloma |
| 13/9/2024 | 09:14 | ALNC | GSK myeloma treatment given breakthrough therapy designation in China |
| 13/9/2024 | 07:00 | UK RNS | GSK PLC China Breakthrough Therapy Designation for Blenrep |
Gsk (GSK) Share Charts1 Year Gsk Chart |
|
1 Month Gsk Chart |
Intraday Gsk Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/10/2024 | 14:30 | Glaxosmithkline - The recovery | 33,374 |
| 03/10/2024 | 12:01 | GSK | 72 |
| 12/9/2024 | 07:16 | GlazoSmithKline - News & Information | 147 |
| 24/9/2023 | 21:42 | GLAXOSMITHKLINE WITH CHARTS & NEWS | 188 |
| 17/4/2023 | 19:25 | Gsk zantac | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-04 15:51:45 | 1,459.50 | 298 | 4,349.31 | O |
| 2024-10-04 15:47:02 | 1,457.81 | 5,874 | 85,631.58 | O |
| 2024-10-04 15:35:53 | 1,459.50 | 2,580 | 37,655.10 | AT |
| 2024-10-04 15:35:34 | 1,459.50 | 4,260 | 62,174.70 | O |
| 2024-10-04 15:35:31 | 1,459.50 | 9,675 | 141,206.63 | O |
| Top Posts |
|---|
Posted at 05/10/2024 09:20 by Gsk Daily Update Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,460.50p.Gsk currently has 4,145,061,122 shares in issue. The market capitalisation of Gsk is £60,476,441,770. Gsk has a price to earnings ratio (PE ratio) of 12.27. This morning GSK shares opened at 1,456p |
Posted at 24/9/2024 12:11 by cumnor Market dynamics changed,for the likes of GSK even-no longer prepared to accept a divi of 3.7% (see it with the likes of LG), given general, political and specific market risks (US litigation for eg) so CEOs need to rethink dividend policy. Emma has not been a successful CEO from shareholders perspective. Divi here needs to be upped to 80p at least (at this share price) to justify investing here. Weak dollar irrelevant-works both ways. Emma should be more outspoken re political implications of Labour tax policies-or threaten to relocate, as I may do for tax reasons. Pfizer did it in Kent-AZN and GSK should follow. |
Posted at 12/9/2024 07:16 by the grumpy old men Issued: 12 September 2024, London UKGSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme · A vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults · mRNA platform elicits strong overall antibody titres with an acceptable safety profile · Data support progression to phase III clinical trials GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine programme. The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care. In both younger and older adults, pre-defined success criteria were met. Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested. These results build on the previous phase II trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile. With these results, the GSK mRNA seasonal influenza vaccine programme will progress into late-stage clinical development. GSK's Chief Scientific Officer, Tony Wood said: "This marks a significant advancement in our mRNA programme and these data support moving into late-stage development. Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season." GSK recently signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and COVID-19 candidate vaccines. GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing. About study NCT06431607 The phase II study assesses the reactogenicity, safety, and immunogenicity of different dose levels of a modified, multivalent vaccine candidate, encoding antigens matched to all three WHO-recommended influenza strains. The study includes 250 healthy younger adults aged 18 to 64 and 250 healthy older adults aged 65 to 85. In each age group, different dose levels were tested in comparison to an age-appropriate, licensed comparator vaccine. |
Posted at 12/9/2024 07:15 by the grumpy old men Issued: 11 September 2024, London UKStatement: Zantac (ranitidine) litigation - Dixon case GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court. GSK does not admit any liability in this settlement. The case will now be dismissed. Since 2019, following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. |
Posted at 20/8/2024 09:07 by tradermichael This is better:GSK PLC (LSE:GSK, NYSE:GSK) has received the green light for a speedier US regulatory process for a potential new cancer drug being developed with a Chinese partner. The pharmaceuticals developer said it has received 'breakthrough therapy designation' from the US Food and Drug Administration (FDA) for the antibody-drug conjugate to treat relapsed or refractory extensive-stage small-cell lung cancer, an aggressive form of lung cancer. Breakthrough therapy designation is given for drugs that have the potential to help treat serious conditions and where preliminary clinical evidence may indicate substantial improvement over currently available therapy. The drug, which currently goes by the name HS-20093 or the code GSK5764227, has shown promising early clinical evidence, the company said, in trials in China. It is being developed by Chinese biopharmaceutical company Hansoh Pharma for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumours. It is in multiple phase I and II clinical trials in China, with GSK's global Phase I trials for GSK5764227 set to begin in the second half of this year. GSK said results from the early-stage clinical trial will be presented at the 2024 World Conference on Lung Cancer taking place in early September and it plans to begin global phase-two trials in the second half of the year. GSK acquired exclusive worldwide rights for GSK5764227 from Hansoh earlier this year. |
Posted at 04/8/2024 14:23 by xtrmntr From the IC.At first sight, the market seemed to shrug off what were objectively decent results for drugmaker GSK (GSK) as the now pure play pharmaceutical company finds its feet and restocks what had become a threadbare research & development pipeline. Getting more value out of hard-to-copy medicines is a priority for GSK, and one where it lags its highly valued competitor AstraZeneca (AZN), but first it has a battalion of troubles to deal with. It is the state of litigation which has given investors a dyspeptic ulcer. The prospect of the company facing long rounds of litigation over its Zantac reflux medicine, with suits alleging its cancer-causing properties having been filed in numerous jurisdictions, was enough to crash the shares earlier this year the main problem being the currently unquantifiable cost of the saga.There is nothing new to report on this front, other than the company's legal costs in relation to this topic have increased, although it does not break these out of the cost of individual litigation.Unsurpris |
Posted at 02/8/2024 10:22 by davius Pick 'n' mix in the broker ratings today...Stifel raises GSK price target to 1,770 (1,740) pence - 'hold' DZ Bank cuts fair value for GSK to 1,650 (1,750) pence - 'hold' JPMorgan cuts GSK price target to 1,550 (1,660) pence - 'underweight' |
Posted at 23/7/2024 15:33 by tradermichael GSK PLC on Tuesday reported "positive" data for testing on three different treatments by ViiV Healthcare, its majority-owned specialist HIV company.The London-based pharmaceutical company firstly said ViiV Healthcare has shared 48-week findings from the phase 4 Paso Doble clinical trial investigating the two-drug regimen Dovato compared with the three-drug regimen Biktarvy for HIV. Dovato comprises dolutegravir and lamivudine, while the Biktarvy regimen consists of bictegravir, emtricitabine and tenofovir alafenamide fumarate. The trial, GSK said, focused on patients "who are virologically suppressed and who could benefit from treatment optimisation". The 48-week results showed that virologically suppressed adults with HIV, if they switched to the Dovato regimen, demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to Biktarvy. Secondly GSK said ViiV, in which Pfizer Inc and Shionogi & Co Ltd also hold minority interests, announced positive data for HIV drug Apretude, or cabotegravir LA for PrEP, in pregnant people. The new maternal safety and pregnancy outcomes and pharmacokinetic findings came from the HIV Prevention Trials Network's 084 open label extension, which evaluated cisgender women in sub-Saharan Africa who became pregnant while using Apretude for HIV pre-exposure prophylaxis, or PrEP. "The findings showed that [Apretude] was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period," GSK said. Finally, GSK and ViiV announced phase 1 study results and in vitro data for VH4524184 or VH184, an investigational integrase strand transfer inhibitor or INSTI. ViiV, GSK said, shared positive in vitro findings showing that VH184 retained its antiviral activity and could be effective in countering second-generation INSTI resistance. Analysis of the phase 1 study, meanwhile, showed that PK and safety data supported the further development of VH184. "The study showed VH184 achieved drug levels in the blood that could potentially exhibit sufficient antiviral activity against the clinically derived INSTI mutations seen in vitro," GSK explained. |
Posted at 05/7/2024 20:08 by xtrmntr It has been a turbulent few months for GSK (GSK) and its investors. The group hiked earnings guidance in May after a strong first quarter, only to see its shares tumble a few weeks later following an inauspicious ruling in the litigation cases relating to heartburn drug Zantac. Now it appears a revised recommendation from US health regulators will hurt sales of one of the company's key vaccines, Arexvy.The jab is designed to protect adults against RSV, a common respiratory virus that can cause serious illness in vulnerable individuals. Both Pfizer (US:PFE) and Moderna (US:MRNA) have produced competitor vaccines, although Arexvy was the first on the market. Last year, the Centers for Disease Control and Prevention (CDC) advised everyone over 60 to get immunised against RSV which was seemingly good news for market leader GSK.However, after reviewing the data, a CDC committee said vaccines should be restricted to the 75-plus cohort, with exceptions for 60-74 years olds with pre-existing conditions. "This move was characterised by one speaker as protecting 'the worried well' from any risks," said UBS analyst Jo Walton. "And if it turns out that re-boosting is not possible, [the decision] keeps the vaccine for use only when a patient is most likely to get a benefit."GSK had also hoped US health authorities would endorse Arexvy for 50-59-year-olds after a recent Food and Drug Administration (FDA) approval for this group. But no such support materialised. According to UBS, this means interested patients would probably have to self-fund their vaccinations at a list price of $300 (£236). Jabs that receive the CDC's seal of approval tend to receive some level of insurance coverage, meaning patients can access them at reduced rates.At present, there isn't enough data on Arexvy's durability for regulators to endorse booster doses and this is crucial for predicting future earnings. Once the results of ongoing trials are published, it's possible that the CDC could expand its recommendations to include vulnerable people in additional age brackets. Brokers are seemingly divided over the longer-term impact of last week's decision, with one Citi analyst stating peak sales of the jab would now "fall materially".Meanwhil |
Posted at 27/6/2024 12:23 by tradermichael GSK pipeline:Phase III: 23 candidates Phase II: 42 candidates Phase I: 22 candidates - across all therapeutic areas According to analysts, GSK price target is 1950.86p with a max estimate of 2580.00p Mean share price target: 2265.43p |
Posted at 02/5/2024 09:24 by geckotheglorious II view”GSK extends share price rally after very healthy results The turnaround at this UK pharmaceutical giant continues following these well-received quarterly results. City writer Graeme Evans explains why investors keep chasing the shares higher. Upgraded guidance and a bigger-than-expected quarterly dividend today moved GSK The drugs giant plans to pay shareholders 15p a share on 11 July, which US bank Jefferies said compared with the City consensus of 14.7p and its own 14.5p estimate. Last year’s quarterly dividend was 14p. The company continues to forecast a full-year payout of 60p a share, which is based on its policy of a 40-60% payout ratio through the investment cycle. Shares rose 40p to 1,713p, taking gains for this year to 16%, after first-quarter revenues of £7.36 billion topped City hopes by 4% and led to a 16% beat on the earnings per share result of 43.1p. The improvement was fuelled by strong sales of shingles vaccine Shingrix, which rose 18% to £945 million on the back of immunisation programmes in Australia and Europe, including the UK. It also benefited from earlier than anticipated supply to GSK’s partner in China. Markets outside the US now represent more than 50% of global Shingrix sales, up from 40% the same quarter a year ago. The vaccine has been launched in 39 countries, the majority of which have average cumulative immunisation rates below 5%. US sales decreased 7% against tougher comparatives, after the country’s immunisation rate at the end of 2023 reached 37% of the more than 120 million US adults currently recommended to receive Shingrix, up seven percentage points since the end of 2022. Arexvy, a respiratory syncytial virus vaccine for older adults, recorded sales of £182 million following its launch in the US in the third quarter of last year. More than seven million of the country’s 83 million adults at risk have so far been protected by Arexvy. In speciality medicines, strong performances in HIV, respiratory and immunology and oncology helped the division’s sales up by 17% to £2.5 billion. Total group sales rose 10% on a constant currency basis, with growth across the first half set to be stronger than the second due to tougher comparisons and the timing of Shingrix sales in China. GSK’s forecasts for 2024 now point to turnover growth towards the upper part of the 5-7% range and core operating profit growth of 9% to 11% compared with 7-10% previously. Core earnings per share growth of 8% to 10% is up from 6-9% given at 2023 results. The drugs pipeline now features 72 vaccines and specialty medicines, with 18 assets in the Phase III later stages of development. Chief executive Emma Walmsley said: “We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data readouts for four phase III medicines.” Taken together with other R&D achievements, she said GSK had strengthened its position in its key therapeutic areas of infectious diseases, HIV, respiratory/immunolo She added: “We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024.”Shares are now within 100p of where they were two years ago prior to the disclosure of US litigation on heartburn drug Zantac. They were just 1,316p in July last year. Jefferies is backing shares to reach 1,950p. It said today: “We are well above consensus 2026 estimates and believe long-acting HIV injectables, vaccines, and new pipeline launches mean profits likely face a blip not cliff on 2028 HIV patent expiries. “We argue given this under-appreciated growth profile, the shares offer attractive risk-reward ahead of potential Zantac class action settlement.” The Zantac issue has overshadowed the company’s attempts to convince the City of its standalone potential since splitting off consumer healthcare operation Haleo It continues to defend itself against the claims but doing so has taken time, with cases scheduled in Illinois, Texas and Nevada between now and March 2025. GSK reached a confidential settlement on a trial due to begin last month in California, a move it said reflected the company’s desire to avoid the distraction related to protracted litigation. It did not admit any liability in the settlement and said it would “continue to vigorously defend itself based on the facts and the science in all other Zantac cases”. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
